These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 15215801

  • 1. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

  • 2. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG, Cerulli A, Frech FH.
    Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
    [Abstract] [Full Text] [Related]

  • 3. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L, Iannazzo S, Zaniolo O.
    Am J Cardiovasc Drugs; 2009 Jun; 9(6):383-92. PubMed ID: 19929036
    [Abstract] [Full Text] [Related]

  • 4. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, VALIANT Investigators.
    Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
    [Abstract] [Full Text] [Related]

  • 5. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 6. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P, Tognoni G, Cohn JN.
    J Card Fail; 2003 Jun 20; 9(3):164-71. PubMed ID: 12815565
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators.
    N Engl J Med; 2001 Dec 06; 345(23):1667-75. PubMed ID: 11759645
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 06; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 9. Economic implications of treatment guidelines for congestive heart failure.
    Shibata MC, Nilsson C, Hervas-Malo M, Jacobs P, Tsuyuki RT.
    Can J Cardiol; 2005 Dec 06; 21(14):1301-6. PubMed ID: 16341301
    [Abstract] [Full Text] [Related]

  • 10. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
    Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN, Val-HeFT Investigators.
    Circulation; 2005 Sep 06; 112(10):1428-34. PubMed ID: 16129801
    [Abstract] [Full Text] [Related]

  • 11. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
    Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R, Valsartan Heart Failure Trial Investigators.
    Circulation; 2003 Sep 16; 108(11):1306-9. PubMed ID: 12939207
    [Abstract] [Full Text] [Related]

  • 12. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 13. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN.
    Circ Heart Fail; 2008 May 15; 1(1):34-42. PubMed ID: 19808268
    [Abstract] [Full Text] [Related]

  • 14. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 15. Valsartan in chronic heart failure.
    Ripley TL.
    Ann Pharmacother; 2005 Mar 21; 39(3):460-9. PubMed ID: 15687480
    [Abstract] [Full Text] [Related]

  • 16. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
    Krum H, Latini R, Maggioni AP, Anand I, Masson S, Carretta E, Ingrillì F, Pettinati G, Glazer R, Tognoni G, Cohn J.
    Int J Cardiol; 2007 Jun 25; 119(1):48-53. PubMed ID: 17049646
    [Abstract] [Full Text] [Related]

  • 17. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
    Baser O, Andrews LM, Wang L, Xie L.
    J Med Econ; 2011 Jun 25; 14(5):576-83. PubMed ID: 21728914
    [Abstract] [Full Text] [Related]

  • 18. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes.
    Cole JA, Norman H, Weatherby LB, Walker AM.
    Pharmacotherapy; 2006 Aug 25; 26(8):1157-64. PubMed ID: 16863491
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.
    Am J Cardiovasc Drugs; 2010 Aug 25; 10(1):55-63. PubMed ID: 20104935
    [Abstract] [Full Text] [Related]

  • 20. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
    Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH.
    Curr Med Res Opin; 2010 Apr 25; 26(4):849-60. PubMed ID: 20141381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.